RESEARCHER PROFILE

Remo Panaccione

← Back to University of Calgary

R

University of Calgary

Inflammatory Bowel DiseaseOcular Diseases and Behçet’s SyndromeRheumatoid Arthritis Research and TherapiesMicroscopic ColitisPsoriasis: Treatment and Pathogenesis

Remo Panaccione works in Inflammatory Bowel Disease, Ocular Diseases and Behçet’s Syndrome, Rheumatoid Arthritis Research and Therapies, Microscopic Colitis, Psoriasis: Treatment and Pathogenesis. Recorded institutional associations include University of Calgary.

1,327Publications
63,835Citations
108H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies

    2017 · 6,054 citations
  2. Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

    2011 · 4,822 citations
  3. Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial

    2006 · 2,245 citations
  4. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

    2015 · 1,844 citations
  5. Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial

    2006 · 1,715 citations
  6. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

    2019 · 1,219 citations
  7. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota

    2002 · 1,144 citations
  8. Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

    2012 · 1,134 citations
  9. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial

    2007 · 1,039 citations
  10. Crohn’s disease

    2020 · 1,023 citations
  11. Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab

    2007 · 965 citations
  12. Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis

    2013 · 963 citations
  13. Natalizumab Induction and Maintenance Therapy for Crohn's Disease

    2005 · 927 citations
  14. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

    2017 · 921 citations
  15. Risk of Surgery for Inflammatory Bowel Diseases Has Decreased Over Time: A Systematic Review and Meta-analysis of Population-Based Studies

    2013 · 892 citations
  16. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

    2011 · 892 citations
  17. The safety of vedolizumab for ulcerative colitis and Crohn's disease

    2016 · 806 citations
  18. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

    2022 · 643 citations
  19. Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial

    2007 · 614 citations
  20. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

    2012 · 591 citations
  21. Invasive potential of gut mucosa-derived fusobacterium nucleatum positively correlates with IBD status of the host

    2011 · 573 citations
  22. Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease

    2023 · 483 citations
  23. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial

    2015 · 460 citations
  24. Association of host genome with intestinal microbial composition in a large healthy cohort

    2016 · 457 citations
  25. Global evolution of inflammatory bowel disease across epidemiologic stages

    2025 · 455 citations

← Return to the university profile